Effect of extended-interval dosing regimen of gonadotropin releasing hormone agonist in the treatment of adenomyosis and endometriosis

Objective To study the effect of extended-interval dosing regimen of gonadotropin releasing hormone agonist(GnRH-a) in the treatment of adenomyosis and endometriosis.Methods Sixty patients suffering from adenomyosis and endometriosis were randomly divided into two groups, extended-interval dosing (study group) and convention dosing(control group).Patients were treated with intramuscular injection of triptorelin 3.75 mg either every 6 weeks of totally four doses regimen(study group) or every 4 weeks of six doses regimen(control group). The changes in the degree of dysmenorrhea and uterine volume were investigated.The level of sexual hormone was also detected both before and after therapy.Results After six months of therapy,the reliving rate of dysmenorrheal was 100% both in the new and convention regimen. The uterine volume was reduced by 37.6% and 39.2%. The level of LH,FSH and E2 significantly decreased(P0.001). The E2 level was reduced to the postmenopausal level. The hormone profile of study group was similar to that of control group(P0.05).Conclusion The use of extended-interval dosing regimen of triptorelin depot in adenomyosis and endometriosis results in a consistent hypoestrogenised state,which is similar to that achieved by conventional regimen. The new regimen significantly reduces the cost of treatment.